Duorui Pharmaceutical Co., Ltd.

Legal Opinion on the 2025 Annual Shareholders Meeting of Tibet Duori Pharmaceutical Co., Ltd.

Announcement of Resolutions from the 2025 Annual Shareholders' Meeting

Announcement on Change of Venue for the Shareholders' Meeting

Continuous Supervision Opinion for the First Quarter of 2026 on the Tender Offer by Wang Qingtai and Cao Xiaobing for Tibet Duorui Pharmaceutical Co., Ltd. by Guojin Securities Co., Ltd.

Announcement on the company's major litigation

CITIC Securities Co., Ltd. Special Review Opinion on the Storage, Management and Use of Raised Funds for 2025 by Tibet Duorui Pharmaceutical Co., Ltd.

Independent Director 2025 Annual Work Report (Qi Fei)

Independent Director 2025 Annual Work Report (Liu Yingfei)

Independent Director 2025 Annual Work Report (Wang Yunguo)

Announcement on Holding the 2025 Annual Online Performance Briefing

2025 Annual Internal Control Audit Report (1)

2025 Annual Internal Control Self-Evaluation Report (1)

Announcement on the Provision for Asset Impairment and Write-off of Assets for 2025

Announcement on the Resignation of the Company's Securities Affairs Representative

Announcement on Confirmation of 2025 Annual Routine Related Transactions

Notice of the 2025 Annual Shareholders' Meeting

Announcement of Resolutions from the Third Meeting of the Third Board of Directors

Announcement on the Proposal Not to Distribute Profits for 2025

2026 First Quarter Report

Special Report on the Annual Storage, Management and Use of Raised Funds

Verification Report on the Annual Storage, Management and Use of Raised Funds

Special Review Opinion on the Deduction of Operating Income

Evaluation Report on the Performance of Accounting Firms in 2025 and the Report of the Board Audit Committee on the Supervision Responsibilities of Accounting Firms

Special Audit Explanation on Non-Operating Fund Occupation and Other Related Fund Transactions

Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions

Special Opinion on the Independence of Independent Directors

2025 Annual Audit Report

2025 Annual Report

2025 Annual Report Summary

Announcement on Requesting Shareholders' Meeting to Authorize the Board of Directors to Handle Matters Related to Small-Scale Quick Financing

Announcement on the change of the legal representative of the company and the completion of industrial and commercial change registration

Announcement of Resolutions from the Second Meeting of the Third Board of Directors

Audit Report (Ruitilian)

Audit Report (Wuhan Duorui)

Audit Report (Haididi)

Announcement on the Transfer of Subsidiary Equity and Related Transactions

Announcement on the progress of share repurchase through centralized bidding reduction

Announcement on Independent Directors Obtaining Independent Director Qualification Certificates

Announcement on the Election of Employee Representative Directors for the Third Board of Directors

Announcement on Change of Office Address and Investor Contact Information

Announcement on the Completion of the Board of Directors' Re-election and the Election of the Chairman, Members of Various Special Committees, and Appointment of Senior Management, Internal Audit Head, and Securities Affairs Representative

Legal Opinion from Beijing Dacheng Law Firm on the First Extraordinary Shareholders' Meeting of Tibet Duorui Pharmaceutical Co., Ltd. in 2026

Announcement of Resolutions from the First Meeting of the Third Board of Directors

Announcement of Resolutions from the First Extraordinary Shareholders' Meeting of 2026

Announcement on Change of Executive Partner of the Company's Shareholder

Written Commitment from Independent Director Candidate (Yang Zhenyuan) Regarding Participation in the Most Recent Independent Director Training and Obtaining Independent Director Qualification Certificate

Written Commitment from Independent Director Candidate (Chen Hui) Regarding Participation in the Most Recent Independent Director Training and Obtaining Independent Director Qualification Certificate

Written Commitment from Independent Director Candidate (Wang Huiqiang) Regarding Participation in the Most Recent Independent Director Training and Obtaining Independent Director Qualification Certificate

"Articles of Association",

"Announcement on the Amendment to the Articles of Association",

"Independent Director Candidate's Declaration and Commitment (Chen Hui)",

"Independent Director Candidate's Declaration and Commitment (Wang Huiqiang)",

"Independent Director Nominator's Declaration and Commitment (Wang Huiqiang)",

"Independent Director Candidate's Declaration and Commitment (Yang Zhenyuan)",

"Independent Director Nominator's Declaration and Commitment (Chen Hui)",

"Independent Director Nominator's Declaration and Commitment (Yang Zhenyuan)",

"Announcement on the Re-election of the Board of Directors",

"Notice on Convening the First Extraordinary Shareholders' Meeting of 2026",

"Announcement of Resolutions of the 27th Meeting of the Second Board of Directors",

"Notice on Convening the 2025 Annual Shareholders' Meeting",

"Independent Director's 2025 Annual Report on Performance of Duties (Qu Chenghui)",

"2025 Independent Director's Annual Performance Report - Chen Jinjun",

Progress Announcement on Redemption of Matured Cash Management Using the Company's Idle Own Funds

Progress Announcement on the Repurchase of Shares Reaching 1%

Progress Announcement on Repurchasing Shares through Centralized Bidding for Reduction

Simplified Report on Changes in Equity (Tibet Jiakang)

Announcement on the Completion of Transfer of Company Shares Acquired by Wang Qingtai and Cao Xiaobing through Tender Offer

Announcement on the Results of the Tender Offer by Wang Qingtai and Cao Xiaobing and the Resumption of Stock Trading

Announcement on Expiration of Tender Offer Period by Wang Qingtai and Cao Xiaobing and Stock Suspension